Ahmed Omar Kaseb Md Cmq

Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC

Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study

Ahmed Kaseb, MD, shares the role of checkpoint inhibitors when alone and combined with anti-CTLA4

It Takes a Team to Improve HCC Outcomes

PeerView Oncology

Optimal Management of HCC: Integrating Novel Therapeutic Approaches Across the Continuum of Care

PeerView Oncology

Multidirectional Management for HCC With Innovative Immunotherapy and Targeted Platforms

PeerView Oncology

Evidence-Based Treatment Selection and Sequencing in Advanced HCC

PeerView Oncology

Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCC

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

Clinical Trials and Future Treatment Options for FLC - Webinar - 14 April 2021

Fibrolamellar Cancer Foundation

Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment

Exploring Challenges in the Treatment of HCC

Targeted Oncology

Reviewing the Current Treatment Landscape for Patients With Hepatocellular Carcinoma

Targeted Oncology

Drs. Abou-Alfa, Goyal, Kaseb, & Singal discuss #HCC at #ASCO23 - https://bit.ly/42g6der

PeerView Oncology

#GLILIVE: Liver Cancers SPORE #OctoberIs4Livers

Global Liver Institute

33- Prof. Ahmed Kaseb

Calibrating HCC Care: Delivering Effective Tx With Modern Immunotherapy and Targeted Approaches

PeerView Oncology

Surah Maryam Heart Soothing Quran Recitation | Muhammad Al Kurdi

38- Prof. Ahmed Kaseb